Orano Med Presentations at the European Association of Nuclear Medicine (EANM) 2019 Annual Congress

10/8/2019

Orano Med, a nuclear biotech company developing Targeted Alpha Therapy with lead-212 (212Pb) announced today upcoming presentations of preclinical studies performed with its partners at the 2019 Annual Congress of the European Association of Nuclear medicine to be held in Barcelona, Spain, on 12-16 October.

Presentations will encompass preclinical data results of ²¹²Pb-NNV003, a CD37 targeting alpha-radioimmunotherapy for the treatment of leukemia and lymphoma, ²¹²Pb-rituxan, a CD20 targeting alpha-radioimmunotherapy for lymphoma, and of CEA-PRIT with ²¹²Pb, a novel pretargeted alpha therapy regimen for the treatment of CEA-positive tumours.

Presentation details are as follows:

Targeted alpha therapy with ²¹²Pb-NNV003 is efficient in treatment of ibrutinib-resistant chronic lymphocytic leukaemia in preclinical model

- Authors: A. Saidi, H. Heyerdahl, A.F. Maaland, J. Torgue, and J. Dahle

- Session: 405 - M2M - Parallel Session: Antibody-Based Radionuclide Therapy

- Abstract: OP-134

- Date / time: Sunday 13 October, 14:30-14:41 CEST

Preclinical study with 212Pb-rituximab as an alpha-radioimmunotherapy for Non-Hodgkin’s Lymphoma

- Authors: I. Quelven, J. Monteil, A. Saidi, J. Torgue, M. Cogne, and S. Durand-Panteix

- Session: 405 - M2M - Parallel Session: Antibody-Based Radionuclide Therapy

- Abstract: OP-135

- Date / time: Sunday 13 October, 14:42-14:52 CEST

Preclinical evaluation of CEA-PRIT, a novel pretargeted alpha therapy regimen for treatment of CEA-positive tumours with 212Pb

- Authors: S. Frost, A. Pichard, A. Haas, H. P. Grimm, A. Mouchotte, A. Colmont, O. Freytag, J. Torgue, S. Colombetti, C. Klein, and P. Umaña

- Session: 405 - M2M - Parallel Session: Antibody-Based Radionuclide Therapy

- Abstract: OP-136

- Date / time: Sunday 13 October, 14:53-15:04 CEST

Abstracts can be found by downloading EANM abstract book here.